Hanmi Tams

PreclinicalSmall molecule

Hanmi Pharmaceutical Company Limited

Hanmi Tams is one of 28 small molecule programs targeting Benign Prostatic Hyperplasia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Benign Prostatic HyperplasiaActive, not recruiting

Benign Prostatic HyperplasiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

36 competitors in Benign Prostatic Hyperplasia

#DrugCompanyPhaseTrials

Flomax

Sanofi

Approved

25 2

Cialis

Eli Lilly

Approved

19 3

Rapaflo

AbbVie

Approved

10 4

Myrbetriq

Astellas

Approved

2 5

Vesicare

Astellas

Approved

1 6

Avodart

Akero Therapeutics

Approved

8 7

Uroxatral

AAdvanz Pharma

Approved

6 8

Propecia

OOrganon and Co

Approved

4 9

Taxol

Minipress

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Benign Prostatic Hyperplasia1 trial

An Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia

Completed· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited··NCT05422677·4,698 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hanmi Tams. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hanmi Tams compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hanmi Tams. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hanmi Pharmaceutical Company Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Hanmi Pharmaceutical Company Limited

Hanmi Tams

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Benign Prostatic Hyperplasia1 trial

References

Drug Info

Quick Facts

Related News